Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Mitochondrial Dynamics as Determinants of Cancer Drug Resistance: A Systematic Review.

Current cancer drug targets·2026
Same author

Application of biochar and seed priming with zinc-oxide nanoparticles for enhancing salinity tolerance in wheat (triticum aestivum L.).

Nanotechnology·2026
Same author

Deciphering Melatonin-Driven Bioenergy Reprogramming Through Integrated Physiological and Metabolomic Analyses in Dunaliella salina.

Applied biochemistry and biotechnology·2026
Same author

Broad-Spectrum Vaccines: Challenges and Opportunities (A Systematic Review).

Current molecular medicine·2026
Same author

K<sub>2</sub>S<sub>2</sub>O<sub>8</sub>-enabled one-pot deaminative C-N bond formation for the synthesis of fused benzimidazopurines and benzimidazo-quinazolines.

Chemical communications (Cambridge, England)·2026
Same author

Advancing protozoan vaccine research: A review of promising candidates and emerging technologies.

Microbial pathogenesis·2026

Related Experiment Video

Updated: Jun 9, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Targeting Drug Metabolism for Triple Negative Breast Cancer: A Systematic Review.

Sakshi Singh1, Swaroop Kumar Pandey1, Jagdip Singh Sohal2

  • 1Department of Biotechnology, Institute of Applied Sciences & Humanities, GLA University, Mathura, 281406, India.

Current Cancer Drug Targets
|June 8, 2026
PubMed
Summary

Targeting metabolic pathways and drug-metabolizing enzymes offers a promising strategy to overcome drug resistance in breast cancer, particularly triple-negative breast cancer (TNBC). This approach aims to improve treatment efficacy and reduce toxicity.

Keywords:
Breast cancerdrug metabolizing enzymesdrug resistancedrugsmetabolismpathways.triple negative breast cancer

More Related Videos

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Related Experiment Videos

Last Updated: Jun 9, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Area of Science:

  • Oncology
  • Metabolic Pathways
  • Pharmacology

Background:

  • Global breast cancer incidence and mortality are rising, with aggressive subtypes like triple-negative breast cancer (TNBC) showing particularly high mortality rates.
  • Despite advancements, escalating mortality underscores the need for novel therapeutic strategies, especially for resistant cancer phenotypes.

Purpose of the Study:

  • To systematically review targeted approaches for managing TNBC by modulating metabolic pathways and drug-metabolizing enzymes.
  • To address emerging challenges and trends in TNBC therapy and drug development.

Main Methods:

  • A systematic literature review was conducted using major scientific databases (PubMed, Google Scholar, ScienceDirect) with a six-year filter.
  • Breast cancer prevalence data were sourced from the Global Cancer Observatory.

Main Results:

  • Modulating metabolic circuits shows potential for reversing cancer resistance phenotypes.
  • Drug-metabolizing enzymes are identified as key therapeutic targets due to their role in xenobiotic metabolism.
  • Selective modulation of these enzymes may enhance drug bioavailability and improve treatment responses.

Conclusions:

  • Targeting metabolic pathways and drug-metabolizing enzymes is crucial for overcoming drug resistance in breast cancer.
  • Differential expression of these pathways and enzymes contributes to resistance mechanisms across cancer subtypes.
  • Precision-targeted interventions are needed to address the metabolic landscape of resistant tumors.